Literature DB >> 6426787

Cellular and subcellular studies of the biotransformation of hexamethylmelamine in rat isolated hepatocytes and intestinal epithelial cells.

P J Borm, M J Mingels, A C Frankhuijzen-Sierevogel, M van Graft, A Hulshoff, J Noordhoek.   

Abstract

The antitumor agent hexamethylmelamine is subject to oxidative metabolic conversion in rat isolated liver and small intestinal cells (conversion 40 times higher in hepatocytes). This N-demethylation is mediated by cytochrome P-450 in the microsomal fractions, and in mitochondrial preparations it has been found to occur via N- methylolpentamethylmelamine . Somehow, pentamethylmelamine, hydroxymethylpentamethylmelamine , or an intermediary metabolite becomes trapped in the intact cell, but the nature of the adduct formed is still unresolved. Pretreatment of rats with 3-methylcholanthrene p.o. caused a 5-fold increase in hexamethylmelamine turnover. Phorone administered in vivo prior to cell preparation (liver and gut) caused an increase in pentamethylmelamine production. The latter results together with results of adding glutathione to cell incubations demonstrate that glutathione contributes to the regulation of cytochrome P-450-mediated N-demethylation of hexamethylmelamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426787

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

Review 1.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 2.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.